scholarly journals Association of MGMT promoter methylation with tumorigenesis features in patients with ovarian cancer: A systematic meta-analysis

2017 ◽  
Vol 6 (1) ◽  
pp. 69-76 ◽  
Author(s):  
Baoli Qiao ◽  
Zhenyu Zhang ◽  
Yanfang Li
Keyword(s):  
Ovarian Cancer ◽  
Promoter Methylation ◽  
Meta Analysis ◽  
Mgmt Promoter Methylation ◽  
Mgmt Promoter

Clinical Significance of O-6-Methylguanine-DNA-Methyltransferase Promoter Methylation in Patients with Esophageal Carcinoma: A Systematic Meta-Analysis

2017 ◽  
Vol 36 (2) ◽  
pp. 89-97 ◽  
Author(s):  
Yan Zhang ◽  
Ti Tong
Keyword(s):  
Esophageal Carcinoma ◽  
Promoter Methylation ◽  
Dna Methyltransferase ◽  
Meta Analysis ◽  
Clinical Stage ◽  
Mgmt Promoter Methylation ◽  
Lymph Node Status ◽  
Tissue Samples ◽  
Methylguanine Dna Methyltransferase ◽  
Mgmt Promoter

Background: The correlation between O-6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and esophageal cancer remains controversial. This study was conducted to evaluate the clinical effect of MGMT promoter methylation on esophageal carcinoma patients. Methods: A literature search was conducted in the PubMed, EMBASE, EBSCO, and Cochrane Library databases. The overall OR and corresponding 95% CI were calculated using the random-effects model. Results: Finally, 17 eligible studies were identified in this meta-analysis; these studies included a total of 1,368 patients with esophageal carcinoma and 1,489 with nonmalignant controls. MGMT promoter methylation was significantly higher in esophageal carcinoma tissue samples than in nonmalignant tissue samples (OR 3.64, p < 0.001). Promoter methylation of the MGMT gene was not associated with gender, cigarette smoking, drinking behavior, or tumor differentiation, but MGMT promoter methylation was correlated with age (≥60 vs. <60 years: OR 1.64, p = 0.028), lymph node status (positive status vs. negative status: OR 2.39, p = 0.024), and clinical stage (stages 3-4 vs. 1-2: OR 10.59, p < 0.001). Conclusions: Our findings suggest that MGMT promoter methylation may be correlated with esophageal cancer carcinogenesis and could be associated with age, lymph node status, and clinical stage.

The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials

2017 ◽  
Vol 233 (1) ◽  
pp. 378-386 ◽  
Author(s):  
Maryam Moradi Binabaj ◽  
Afsane Bahrami ◽  
Soodabeh ShahidSales ◽  
Marjan Joodi ◽  
Mona Joudi Mashhad ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Promoter Methylation ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Mgmt Promoter Methylation ◽  
Mgmt Promoter

The Association Between MGMT Promoter Methylation and Patients with Gastric Cancer: A Meta-Analysis

2017 ◽  
Vol 21 (4) ◽  
pp. 213-221 ◽  
Author(s):  
Xiaolong Yuan ◽  
Jifei Xu ◽  
Weiyang Fang ◽  
Zhenfeng Zhao ◽  
Fan Wang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Promoter Methylation ◽  
Meta Analysis ◽  
Mgmt Promoter Methylation ◽  
Mgmt Promoter

The Prognosis of MGMT Promoter Methylation in Glioblastoma Patients of Different Race: A Meta-analysis

2014 ◽  
Vol 39 (12) ◽  
pp. 2277-2287 ◽  
Author(s):  
Haiyu Yang ◽  
Danping Wei ◽  
Kunxian Yang ◽  
Wenru Tang ◽  
Ying Luo ◽  
...  
Keyword(s):  
Promoter Methylation ◽  
Meta Analysis ◽  
Mgmt Promoter Methylation ◽  
Mgmt Promoter

MGMT Promoter Methylation and Glioblastoma Prognosis: A Systematic Review and Meta-analysis

2013 ◽  
Vol 44 (4) ◽  
pp. 281-290 ◽  
Author(s):  
Yang Chen ◽  
Fulan Hu ◽  
Yiheng Zhou ◽  
Wangyang Chen ◽  
Hongying Shao ◽  
...  
Keyword(s):  
Systematic Review ◽  
Promoter Methylation ◽  
Meta Analysis ◽  
Mgmt Promoter Methylation ◽  
Mgmt Promoter

scholarly journals Association Between MGMT Promoter Methylation and Breast Cancer: a Meta-Analysis

2017 ◽  
Vol 42 (6) ◽  
pp. 2430-2440 ◽  
Author(s):  
Nairui An ◽  
Yu Shi ◽  
Peng Ye ◽  
Zhongya Pan ◽  
Xinghua Long
Keyword(s):  
Breast Cancer ◽  
Promoter Methylation ◽  
Dna Methyltransferase ◽  
Histological Grade ◽  
Meta Analysis ◽  
Methylation Status ◽  
Mgmt Promoter Methylation ◽  
P Value ◽  
Breast Cancer Patients ◽  
Mgmt Promoter

Background/Aims: Numerous studies have suggested that the promoter methylation status of O6-methylguanine-DNA methyltransferase (MGMT) is significantly associated with breast cancer. However, these studies have not demonstrated consistent results. Methods: To obtain more accurate results for this possible association, we performed a meta-analysis-based study using the relevant data. A total of 14 articles were included in this meta-analysis. Results: Our study showed that the frequency of MGMT promoter methylation was significantly higher in patients with breast cancer than non-breast cancer subjects with an Odds Ratio (OR) of 4.47, a 95% Confidence Interval (CI) ranging between 1.95 - 10.25 and a P value of 0.0004. Moreover, MGMT methylation was significantly associated with the negative expression of the MGMT protein (OR = 4.65, 95%CI = 2.66 - 8.12, P < 0.00001), Oestrogen Receptor (ER)-negative tumours (OR = 1.79, 95%CI = 1.09 - 2.93, P = 0.02), postmenopausal status (OR =1.84, 95%CI = 1.18 - 2.87, P = 0.007) and histological grade III tumours (OR = 2.49, 95%CI = 1.53 - 4.07, P = 0.0003) in breast cancer patients. However, breast cancer was not significantly correlated with lymph node metastasis (OR = 1.19, 95%CI = 0.83 - 1.70, P = 0.35), Progesterone Receptor (PR) status (OR = 1.08, 95%CI = 0.58 - 2.00, P = 0.81), Human epidermal growth factor receptor - 2（HER-2/neu）status (OR = 1.01, 95%CI = 0.65 - 1.57, P = 0.97), P53 mutation (OR = 1.30, 95%CI = 0.76 - 2.21, P = 0.34) and age > 50 (OR = 1.07, 95%CI = 0.46 - 2.51, P = 0.88). Conclusions: Our study suggests that MGMT promoter methylation may be an early biomarker for the diagnosis of breast cancer.

scholarly journals Changes of O6-Methylguanine DNA Methyltransferase (MGMT) Promoter Methylation in Glioblastoma Relapse—A Meta-Analysis Type Literature Review

Cancers ◽  
2019 ◽  
Vol 11 (12) ◽  
pp. 1837 ◽  
Author(s):  
Jonas Feldheim ◽  
Almuth F. Kessler ◽  
Camelia M. Monoranu ◽  
Ralf-Ingo Ernestus ◽  
Mario Löhr ◽  
...  
Keyword(s):  
Promoter Methylation ◽  
Dna Methyltransferase ◽  
Selective Pressure ◽  
Meta Analysis ◽  
Mgmt Promoter Methylation ◽  
Clinical Implications ◽  
Methylguanine Dna Methyltransferase ◽  
Response To Chemotherapy ◽  
Mgmt Promoter ◽  
Technical Issues

Methylation of the O6-methylguanine DNA methyltransferase (MGMT) promoter has emerged as strong prognostic factor in the therapy of glioblastoma multiforme. It is associated with an improved response to chemotherapy with temozolomide and longer overall survival. MGMT promoter methylation has implications for the clinical course of patients. In recent years, there have been observations of patients changing their MGMT promoter methylation from primary tumor to relapse. Still, data on this topic are scarce. Studies often consist of only few patients and provide rather contrasting results, making it hard to draw a clear conclusion on clinical implications. Here, we summarize the previous publications on this topic, add new cases of changing MGMT status in relapse and finally combine all reports of more than ten patients in a statistical analysis based on the Wilson score interval. MGMT promoter methylation changes are seen in 115 of 476 analyzed patients (24%; CI: 0.21–0.28). We discuss potential reasons like technical issues, intratumoral heterogeneity and selective pressure of therapy. The clinical implications are still ambiguous and do not yet support a change in clinical practice. However, retesting MGMT methylation might be useful for future treatment decisions and we encourage clinical studies to address this topic.

Sign in / Sign up

Export Citation Format

Share Document